Assessing Albireo Pharma [Seeking Alpha]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
SummaryAlbireo Pharma like so many small biotech names has been hit hard during the recent COVID-19 market meltdown.However, the company's lead asset, odevixibat, is a pipeline within a product, with its multiple clinical indications adding to blockbuster potential.Several 2020 catalysts and recent beneficial owner buying merit further consideration.A full investment analysis is provided in the paragraphs below.Fighting cruelty with just criticism is like fighting against sword with a stickIt is nice to see the new trading week begin with some optimism and a big rally. Today we look at an interesting 'Tier 4Company OverviewAlbireo Pharma, Inc. (ALBOAZNBile Acid BiologyTwo of the company's candidates are known as ileal bile acid transporter (IBAT) inhibitors. The liver uses cholesterol - either from foods we eat or self-manufactured - to produce bile acids. Once manufactured, bile acids are transported and stored in the gall bladder. In response to food ingestion, the gall bladder cont
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- A Look At Mirum Pharmaceuticals (MIRM) Valuation After Strong Long Term Share Performance [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $117.00 to $125.00. They now have a "buy" rating on the stock.MarketBeat
- Mirum Pharmaceuticals (MIRM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $130.00 price target on the stock.MarketBeat
- Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver DiseasesBusiness Wire
MIRM
Earnings
- 2/25/26 - Miss
MIRM
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- MIRM's page on the SEC website